Poplin E, Thompson B, Whitacre M, Aisner J
Cancer Treat Rep. 1987 Mar;71(3):291-6.
Two hundred twenty-three patients between 29 and 78 years of age with small cell cancer of the lung were studied in serial protocols at the University of Maryland Cancer Center from 1975 to 1982. Each of these patients received chemotherapy consisting of doxorubicin, cyclophosphamide, and etoposide. In this paper we explore age and its interaction with the patient's extent of disease as it relates to clinical outcome variables such as the achievement of a complete response (CR), survival times, and various measures of toxicity. Preliminary evidence is found to suggest that an age-extent of disease interaction affects both the probability of obtaining a CR and the length of survival. Patients of all ages can benefit from treatment of small cell carcinoma of the lung, with CR as the treatment goal. However, increased toxicity and early death remain as barriers to successful treatment of the elderly.
1975年至1982年期间，马里兰大学癌症中心按照系列方案对223名年龄在29岁至78岁之间的小细胞肺癌患者进行了研究。这些患者均接受了由阿霉素、环磷酰胺和依托泊苷组成的化疗。在本文中，我们探讨年龄及其与患者疾病程度的相互作用，因为这与临床结局变量相关，如完全缓解（CR）的达成、生存时间以及各种毒性指标。初步证据表明，年龄与疾病程度的相互作用会影响获得CR的概率和生存时长。以CR为治疗目标，所有年龄段的小细胞肺癌患者都能从治疗中获益。然而，毒性增加和早期死亡仍是老年患者成功治疗的障碍。
